Engineered UTRs for AAV Protein Expression Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing adeno-associated virus (AAV) vectors lack efficient systems for controlled expression of AAV capsid and replication proteins, limiting the production of stable and effective gene therapy materials.
Innovation Solution
The development of engineered untranslated regions (UTRs) within viral expression constructs, which include specific promoter sequences and hairpin structures, to control the expression of AAV capsid and replication proteins, such as VP1, VP2, VP3, Rep78, and Rep52, thereby modulating protein production and ratios.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional methods are used for producing AAV vectors, then production can proceed with standard systems, but controlled expression of AAV capsid and replication proteins is limited
Solution Approach 1:
The patent modifies the untranslated regions (UTRs) of AAV genetic sequences to control protein expression. Specifically, it engineers the 5' UTR and 3' UTR sequences of cap and rep genes to regulate the translation and stability of mRNA, thereby controlling the expression levels of capsid proteins (VP1, VP2, VP3) and replication proteins (Rep78, Rep68, Rep52, Rep40) without adding complex regulatory systems
Solution Approach 2:
The patent uses engineered UTR sequences as intermediary elements that mediate between the promoter and the coding sequences. These UTRs act as regulatory intermediaries that control translation initiation, mRNA stability, and protein expression ratios, enabling precise control of AAV protein production through sequence design rather than complex regulatory circuits
2Productivity
If standard production systems are used, then manufacturing is simpler, but protein production capability and stability of AAV vectors are reduced
Solution Approach 1:
The patent engineers specific UTR sequences with optimized nucleotide compositions and secondary structures to enhance protein production. The 5' UTR sequences are designed with specific stem-loop structures that promote translation initiation, while 3' UTR sequences are optimized for mRNA stability. These parameter changes in sequence composition directly increase capsid and replication protein production efficiency
Solution Approach 2:
The patent separately engineers the 5' UTR and 3' UTR regions of different AAV genes (cap and rep) to independently control expression of each protein. This segmentation allows independent optimization of translation efficiency and mRNA stability for each gene product, enabling precise control over the production of VP1, VP2, VP3, Rep78, Rep68, Rep52, and Rep40 proteins
3Manufacturing precision
If conventional expression control is used, then construct design is simpler, but precision in controlling protein expression ratios is limited
Solution Approach 1:
The patent precisely controls protein expression ratios by engineering specific nucleotide sequences in the UTR regions. The 5' UTR sequences are designed with specific secondary structures that differentially regulate translation initiation for cap and rep mRNAs, while 3' UTR sequences control mRNA degradation rates. These parameter changes enable precise control of the VP1:VP2:VP3 and Rep78:Rep68:Rep52:Rep40 ratios
Solution Approach 2:
The engineered UTR sequences serve as intermediary regulatory elements that mediate the expression ratios between different AAV genes. By designing specific sequence features in these intermediary UTR regions, the patent controls the relative expression levels of multiple proteins from a single promoter, achieving precise manufacturing precision without complex multi-promoter systems
Data Source
AI summary
The present disclosure describes methods and systems for use in the production of recombinant adeno-associated virus (rAAV) particles. In certain embodiments, the production process and system include engineered untranslated regions (UTR) which allow for the controlled expression of AAV capsid proteins, such as VP1, VP2 and VP3. In certain embodiments, the production process and system include engineered untranslated regions (UTR) which allow for the controlled expression of non-structural AAV replication proteins, such as Rep78 and Rep52.